encoding a protein associated with said ocular disease, whereby said exogenous nucleic acid is expressed, wherein said disease is lysosomal storage disease.--.

REMARKS

Claims 1 and 10 have been added as independent claims. Claims 2-9 have been added as claims depending from Claim 1. Support for these claims is found throughout the specification. Specifically, support for claims 1-9 is found at page 9, line 30 to page 10, line 6. Support for Claim 10 is found at page 10, lines 18-31.

Applicant believes that the claims are now in form for allowance. Applicant respectfully requests such a favorable finding and processing of the application to issuance. If there are any unresolved issues, the Examiner is requested to call the attorney signing below at (415) 781-1989.

Respectfully submitted,

FLEHR HOHBACH TEST
ALBRITTON & HERBERT LLP

Dolly A. Vance
Reg. No. 39,054

FLEHR HOHBACH TEST
ALBRITTON & HERBERT LLP
4 Embarcadero Center
Suite 3400
San Francisco, CA 94111
(415) 781-1989
Date: August 3, 2000

1026126

APPENDIX

1. A method of treating a genetic ocular disease comprising incorporating exogenous nucleic acid into an *in situ* ocular cell under conditions permissive for the uptake of said exogenous nucleic acid, said exogenous nucleic acid encoding a protein associated with said ocular disease, whereby said exogenous nucleic acid is expressed.

2. The method of claim 1, and wherein said genetic ocular disease is autosomal retinitis pigmentosa.

3. The method of claim 1, and wherein said genetic ocular disease is autosomal dominant retinitis punctata albescens.

4. The method of claim 1, and wherein said genetic ocular disease is butterfly-shaped pigment dystrophy of the fovea.

5. The method of claim 1, and wherein said genetic ocular disease is adult vitelliform macular dystrophy.

6. The method of claim 1, and wherein said genetic ocular disease is Norrie's disease.

7. The method of claim 1, and wherein said genetic ocular disease is blue cone monochromasy.

8. The method of claim 1, and wherein said genetic ocular disease is choroideremia.

9. The method of claim 1, and wherein said genetic ocular disease is gyrate atrophy.

10. A method of treating an ocular disease comprising incorporating exogenous nucleic acid into an *in situ* ocular cell under conditions permissive for the uptake of said exogenous nucleic acid, said exogenous nucleic acid encoding a protein associated with said ocular disease, whereby said exogenous nucleic acid is expressed, wherein said disease is lysosomal storage disease.